The structural diversity, adaptive potential, and dynamic evolution of on-target mutations not only exemplify tumor cell remodeling under selective pressure from targeted therapy but also provide a precise framework for the rational design of next-generation, broad-spectrum ALK inhibitors. The gene discussed is ALK; the disease is neoplasm.